APP and Cognitive impairment: Reduced 3-MST expression [83]; reduced 3-MST activity and 3-MP levels [82] in APP/PS1 mice brain. Increased APP, BACE-1, and Aβ42 levels were observed in APP/PS1 mice compared to WT mice; however, NaSH treatment led to activation of Nrf2/ARE pathway [83]. Attenuation of neuroinflammation (TNFα, IL-6), elevated Aβ42 levels and oxidative stress in APP/PS1 mice by 3-MP prodrug, sulfanegen with restoration of cognitive impairment [82].